Lee Hambright
Stock Analyst at Bernstein
(3.23)
# 1,041
Out of 5,163 analysts
40
Total ratings
50%
Success rate
3.23%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Outperform | $380 → $330 | $219.84 | +50.11% | 3 | Feb 19, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $154 → $125 | $108.03 | +15.71% | 7 | Jan 23, 2026 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $740 → $750 | $472.16 | +58.84% | 4 | Jan 23, 2026 | |
| MDLN Medline | Initiates: Outperform | $49 | $41.46 | +18.19% | 1 | Jan 12, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $97 → $99 | $93.20 | +6.22% | 2 | Jan 9, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Market Perform | $18 → $25 | $21.59 | +15.79% | 2 | Jan 9, 2026 | |
| SYK Stryker | Maintains: Outperform | $450 → $465 | $336.77 | +38.08% | 4 | Jan 9, 2026 | |
| MDT Medtronic | Maintains: Outperform | $111 → $112 | $87.14 | +28.53% | 4 | Jan 9, 2026 | |
| JNJ Johnson & Johnson | Maintains: Market Perform | $193 → $208 | $241.52 | -13.88% | 6 | Jan 9, 2026 | |
| DXCM DexCom | Maintains: Outperform | $84 → $86 | $64.24 | +33.87% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $92 → $100 | $69.13 | +44.66% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $81.81 | +65.02% | 3 | Mar 16, 2022 |
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $380 → $330
Current: $219.84
Upside: +50.11%
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $154 → $125
Current: $108.03
Upside: +15.71%
Intuitive Surgical
Jan 23, 2026
Maintains: Outperform
Price Target: $740 → $750
Current: $472.16
Upside: +58.84%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $49
Current: $41.46
Upside: +18.19%
Zimmer Biomet Holdings
Jan 9, 2026
Maintains: Market Perform
Price Target: $97 → $99
Current: $93.20
Upside: +6.22%
Tandem Diabetes Care
Jan 9, 2026
Maintains: Market Perform
Price Target: $18 → $25
Current: $21.59
Upside: +15.79%
Stryker
Jan 9, 2026
Maintains: Outperform
Price Target: $450 → $465
Current: $336.77
Upside: +38.08%
Medtronic
Jan 9, 2026
Maintains: Outperform
Price Target: $111 → $112
Current: $87.14
Upside: +28.53%
Johnson & Johnson
Jan 9, 2026
Maintains: Market Perform
Price Target: $193 → $208
Current: $241.52
Upside: -13.88%
DexCom
Jan 9, 2026
Maintains: Outperform
Price Target: $84 → $86
Current: $64.24
Upside: +33.87%
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $69.13
Upside: +44.66%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $81.81
Upside: +65.02%